14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BMGL vs GRML: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Basel Medical Group Ltd (BMGL) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMGL carries a Unified Composite Score of 41.0/100 (SELL) at $0.31 (N/M Forward P/E, -3.7% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. BMGL 41.0/100 SELL), BMGL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-3.7% vs. N/A operating margin) and revenue trajectory (+63.0% vs. N/A YoY).
Technical & Structure Timing Caution: BMGL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.9); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BMGL vs GRML. Trailing 12-month operating profitability (BMGL -3.7% vs GRML N/A) and valuation multiples (BMGL N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BMGL vs GRML Key Questions & Quantitative Answers
As of Nov 16, 2026, Basel Medical Group Ltd (BMGL) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BMGL carries a Unified Composite Score of 41.0/100 (SELL) at $0.31 (N/M Forward P/E, -3.7% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. BMGL 41.0/100 SELL), BMGL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (-3.7% vs. N/A operating margin) and revenue trajectory (+63.0% vs. N/A YoY). Technical & Structure Timing Caution: BMGL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 17.9); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BMGL leads the Growth & Scale pillar: BMGL posts +63.0% YoY revenue growth and +0.0% YoY earnings growth on $22M TTM revenue (38.8% gross margin, -3.7% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BMGL generates $22M in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, BMGL deploys 42.5% of Rev ($9.1M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.
BMGL screens cheaper on headline valuation multiples. BMGL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-2.0% EBITDA margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BMGL (-28.7% ROE) versus GRML (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, BMGL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-2.08β · 332% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.